A rare case of idiopathic cholestasis: Clinical conundrums complicating enzalutamide therapy in metastatic prostate cancer

Abstract

Abstract Current safety data affirms enzalutamide does not cause clinically significant liver dysfunction that warrant therapy cessation. Therefore, clinicians should not withhold potentially successful therapy merely for suspected hepatotoxicity or PnC.

Keywords

• adverse drug reactions
• cholestasis
• enzalutamide
• paraneoplastic syndrome
• prostate cancer